TradingKey

More Details of Zoetis Inc Company

Zoetis Inc. is a global animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The Company operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).

Company Info

Ticker SymbolZTS

Company nameZoetis Inc

IPO dateFeb 01, 2013

Founded at2012

CEOMs. Kristin C. Peck

Number of employees13800

Security typeOrdinary Share

Fiscal year-endFeb 01

Address10 Sylvan Way

CityPARSIPPANY

Stock exchangeNYSE Consolidated

CountryUnited States of America

Postal code07054

Phone19738227000

Websitehttps://www.zoetis.com/

Ticker SymbolZTS

IPO dateFeb 01, 2013

Founded at2012

Company Executives

Name

Name/Position

Position

Shareholding

Change

Ms. Kristin C. Peck

Chief Executive Officer, Director

95.01K

+0.02%

Mr. Michael B. Mccallister

Non-Executive Independent Chairman of the Board

25.86K

-6.61%

Mr. Gregory (Greg) Norden

Independent Director

16.95K

+12.20%

Ms. Louise M. Parent

Independent Director

15.26K

--

Mr. Frank A. D'amelio

Independent Director

14.81K

--

Mr. Sanjay Khosla

Independent Director

9.81K

--

Mr. Robert J. Polzer, Ph.D.

Executive Vice President, President - Research and Development

6.19K

+0.39%

Ms. Rimma Driscoll

Executive Vice President and Head of Global Strategy, Commercial and Business Development, and Global BioDevices

5.19K

+8.28%

Ms. Vanessa Broadhurst

Independent Director

2.82K

+51.75%

Mr. Jamie Brannan

Executive Vice President, Chief Commercial Officer

2.59K

+19.25%

Name

Name/Position

Position

Shareholding

Change

Ms. Kristin C. Peck

Chief Executive Officer, Director

95.01K

+0.02%

Mr. Michael B. Mccallister

Non-Executive Independent Chairman of the Board

25.86K

-6.61%

Mr. Gregory (Greg) Norden

Independent Director

16.95K

+12.20%

Ms. Louise M. Parent

Independent Director

15.26K

--

Mr. Frank A. D'amelio

Independent Director

14.81K

--

Mr. Sanjay Khosla

Independent Director

9.81K

--

Revenue Breakdown

Currency: USDUpdated: Sun, Jul 6

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

By BusinessUSD

Name

Revenue

Proportion

Parasiticides

562.00M

25.32%

Vaccines

447.00M

20.14%

Dermatology

390.00M

17.57%

Anti-infectives

249.00M

11.22%

Pain and sedation

210.00M

9.46%

Other

362.00M

16.31%

By RegionUSD

Name

Revenue

Proportion

United States

1.18B

53.29%

Other emerging markets

248.00M

11.17%

Other Developed

133.00M

5.99%

Brazil

88.00M

3.96%

United Kingdom

77.00M

3.47%

Other

491.00M

22.12%

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

Parasiticides

562.00M

25.32%

Vaccines

447.00M

20.14%

Dermatology

390.00M

17.57%

Anti-infectives

249.00M

11.22%

Pain and sedation

210.00M

9.46%

Other

362.00M

16.31%

Shareholding Stats

Updated: Fri, Feb 21

Shareholders

Shareholder Types

Shareholders

Proportion

The Vanguard Group, Inc.

9.29%

BlackRock Institutional Trust Company, N.A.

5.20%

State Street Global Advisors (US)

4.45%

State Farm Insurance Companies

3.79%

Geode Capital Management, L.L.C.

2.47%

Other

74.80%

Shareholders

Proportion

The Vanguard Group, Inc.

9.29%

BlackRock Institutional Trust Company, N.A.

5.20%

State Street Global Advisors (US)

4.45%

State Farm Insurance Companies

3.79%

Geode Capital Management, L.L.C.

2.47%

Other

74.80%

Shareholder Types

Shareholders

Proportion

Investment Advisor

47.94%

Investment Advisor/Hedge Fund

32.14%

Research Firm

4.83%

Insurance Company

3.89%

Bank and Trust

2.67%

Pension Fund

2.51%

Sovereign Wealth Fund

1.21%

Hedge Fund

1.20%

Family Office

0.14%

Other

3.47%

Institutional Shareholding

Updated: Tue, Jul 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q2

3264

431.39M

96.89%

-5.29M

2025Q1

3284

432.42M

97.12%

-4.21M

2024Q4

3199

430.60M

96.14%

-9.58M

2024Q3

3090

434.14M

95.81%

-13.19M

2024Q2

3062

437.75M

95.94%

-9.33M

2024Q1

3060

439.45M

96.16%

-2.63M

2023Q4

3074

438.13M

95.43%

-2.08M

2023Q3

2966

434.04M

94.28%

-3.00M

2023Q2

2949

430.67M

93.19%

-11.77M

2023Q1

2913

436.42M

94.33%

-5.14M

Shareholder Activity

Name

Shares Held

Proportion

Change

Chg %

Date

The Vanguard Group, Inc.

41.36M

9.29%

+189.52K

+0.46%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

23.15M

5.2%

+208.71K

+0.91%

Mar 31, 2025

State Street Global Advisors (US)

19.80M

4.45%

-46.05K

-0.23%

Mar 31, 2025

State Farm Insurance Companies

16.88M

3.79%

-120.91K

-0.71%

Mar 31, 2025

Geode Capital Management, L.L.C.

10.99M

2.47%

+368.11K

+3.47%

Mar 31, 2025

AllianceBernstein L.P.

10.86M

2.44%

-952.97K

-8.07%

Mar 31, 2025

Polen Capital Management, LLC

8.80M

1.98%

+1.31M

+17.55%

Mar 31, 2025

Wellington Management Company, LLP

6.07M

1.36%

-893.17K

-12.84%

Mar 31, 2025

Wells Fargo Advisors

6.01M

1.35%

+338.64K

+5.97%

Mar 31, 2025

BlackRock Asset Management Ireland Limited

5.36M

1.2%

+511.23K

+10.54%

Mar 31, 2025

Related ETFs

Updated: Sun, Jul 6

Name

Proportion

ProShares Pet Care ETF

10%

VanEck Agribusiness ETF

7.86%

VanEck Pharmaceutical ETF

4.91%

Honeytree US Equity ETF

4.41%

iShares U.S. Pharmaceuticals ETF

4.29%

First Trust NASDAQ Pharmaceuticals ETF

4.08%

SPDR S&P Pharmaceuticals ETF

3.95%

Natixis Vaughan Nelson Select ETF

3.88%

AAM Sawgrass US Large Cap Quality Growth ETF

2.51%

Jensen Quality Growth ETF

2.44%

ProShares Pet Care ETF

Proportion10%

VanEck Agribusiness ETF

Proportion7.86%

VanEck Pharmaceutical ETF

Proportion4.91%

Honeytree US Equity ETF

Proportion4.41%

iShares U.S. Pharmaceuticals ETF

Proportion4.29%

First Trust NASDAQ Pharmaceuticals ETF

Proportion4.08%

SPDR S&P Pharmaceuticals ETF

Proportion3.95%

Natixis Vaughan Nelson Select ETF

Proportion3.88%

AAM Sawgrass US Large Cap Quality Growth ETF

Proportion2.51%

Jensen Quality Growth ETF

Proportion2.44%

Dividend

A total of 2.94B USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

Dec 12, 2024

ZTS.NB Interim Cash Dividend of gross USD 0.5 paid on Mar 04, 2025 going ex on Jan 21, 2025

Jan 21, 2025

Mar 04, 2025

Jan 21, 2025

Oct 10, 2024

ZTS.NB Final Cash Dividend of gross USD 0.432 paid on Dec 03, 2024 going ex on Oct 31, 2024

Oct 31, 2024

Dec 03, 2024

Oct 31, 2024

May 22, 2024

ZTS.NB Interim Cash Dividend of gross USD 0.432 paid on Sep 04, 2024 going ex on Jul 18, 2024

Jul 18, 2024

Sep 04, 2024

Jul 18, 2024

Feb 06, 2024

ZTS.NB Interim Cash Dividend of gross USD 0.432 paid on Jun 04, 2024 going ex on Apr 18, 2024

Apr 19, 2024

Jun 04, 2024

Apr 18, 2024

Dec 07, 2023

ZTS.NB Interim Cash Dividend of gross USD 0.432 paid on Mar 01, 2024 going ex on Jan 18, 2024

Jan 19, 2024

Mar 01, 2024

Jan 18, 2024

Oct 12, 2023

ZTS.NB Final Cash Dividend of gross USD 0.375 paid on Dec 01, 2023 going ex on Oct 31, 2023

Nov 01, 2023

Dec 01, 2023

Oct 31, 2023

May 11, 2023

ZTS.NB Interim Cash Dividend of gross USD 0.375 paid on Sep 01, 2023 going ex on Jul 20, 2023

Jul 21, 2023

Sep 01, 2023

Jul 20, 2023

Feb 08, 2023

ZTS.NB Interim Cash Dividend of gross USD 0.375 paid on Jun 01, 2023 going ex on Apr 20, 2023

Apr 21, 2023

Jun 01, 2023

Apr 20, 2023

Dec 08, 2022

ZTS.NB Interim Cash Dividend of gross USD 0.375 paid on Mar 01, 2023 going ex on Jan 19, 2023

Jan 20, 2023

Mar 01, 2023

Jan 19, 2023

Oct 13, 2022

ZTS.NB Final Cash Dividend of gross USD 0.325 paid on Dec 01, 2022 going ex on Oct 31, 2022

Nov 01, 2022

Dec 01, 2022

Oct 31, 2022

Stock Split

Date

Type

Ratio

No Data

Date

Type

Ratio

No Data

Zoetis Inc

146.130USD

Zoetis Inc

146.130

Overview

Company

Financials